Chelsea Therapeutics Announces FDA Advisory Committee to Review Northera « New Drug Approvals

Chelsea Therapeutics Announces FDA Advisory Committee to Review Northera « New Drug Approvals:

'via Blog this'

GT Biologics obtains FDA orphan drug designation for paediatric Crohn’s drug « New Drug Approvals

GT Biologics obtains FDA orphan drug designation for paediatric Crohn’s drug « New Drug Approvals:

'via Blog this'

Keryx’s NDA for kidney drug accepted for filing by US FDA » All About Drugs

Keryx’s NDA for kidney drug accepted for filing by US FDA » All About Drugs:

'via Blog this'

The U.S. Food and Drug Administration approved Adempas (riociguat) to treat adults with two forms of pulmonary hypertension. « New Drug Approvals

The U.S. Food and Drug Administration approved Adempas (riociguat) to treat adults with two forms of pulmonary hypertension. « New Drug Approvals:

'via Blog this'

Glaxo Plans to File for Malaria Vaccine Approval Next Year « New Drug Approvals

Glaxo Plans to File for Malaria Vaccine Approval Next Year « New Drug Approvals:

'via Blog this'

Finerenone (BAY 94-8862), BAYER’S next generation oral, non-steroidal Mineralocorticoid Receptor antagonist which blocks the deleterious effects of aldosterone « New Drug Approvals

Finerenone (BAY 94-8862), BAYER’S next generation oral, non-steroidal Mineralocorticoid Receptor antagonist which blocks the deleterious effects of aldosterone « New Drug Approvals:

'via Blog this'

Copanlisib (BAY 80-6946), Bayer’s novel, oral phosphatidylinositol-3 kinases (PI3K) inhibitor « New Drug Approvals

Copanlisib (BAY 80-6946), Bayer’s novel, oral phosphatidylinositol-3 kinases (PI3K) inhibitor « New Drug Approvals:

'via Blog this'